Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma

25 Oct 2018

Abstract excerpt

Despite improvements in overall survival, only a modest percentage of patients survives high-risk medulloblastoma. The devastating side effects of radiation and chemotherapy substantially reduce quality of life for surviving patients. Here, using genomic screens, we identified miR-584-5p as a potent therapeutic adjuvant that potentiates medulloblastoma to radiation and vincristine. MiR-584-5p inhibited...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Glioma Diagnosis and Treatment
Share to Histone Deacetylase Inhibitors Research
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30382096
DOI: 10.1038/s41467-018-06808-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastomaPMID 30382096Read ↗

Integrated genomic analysis identifies the mitotic checkpoint kinase WEE1 as a novel therapeutic target in medulloblastomaSemantic proximity Read ↗

New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology.Semantic proximity Read ↗

The Neurodevelopmental and Molecular Landscape of Medulloblastoma Subgroups: Current Targets and the Potential for Combined TherapiesSemantic proximity Read ↗

The molecular classification of medulloblastomaSemantic proximity Read ↗

Targeting synthetic lethality between non-homologous end joining and radiation in very-high-risk medulloblastomaSemantic proximity Read ↗

Knockdown of Musashi-1 enhances chemotherapeutic sensitivity and apoptosis in Group 3/4 medulloblastomas cellsSemantic proximity Read ↗

Emerging treatments and gene expression profiling in high-risk medulloblastoma.Semantic proximity Read ↗

Medulloblastoma biology in the post-genomic era.Semantic proximity Read ↗

Targeting synthetic lethality between non-homologous end joining and radiation in very high-risk SHH medulloblastomaSemantic proximity Read ↗

Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.Semantic proximity Read ↗

Musashi-1 regulates cell cycle and confers resistance to cisplatin treatment in Group 3/4 medulloblastomas cellsSemantic proximity Read ↗

Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.